China’s speed in generating first-in-human data has catalyzed a race across the globe to reshape regulatory requirements to compete. BioCentury’s analysts, along with special guests Detlev Mennerich, head of Boehringer Ingelheim Venture Fund, and Mehdi Ainouche, partner at Jeito Capital, discussed where Europe fits in that landscape and other takeaways from the 26th annual Bio€quity Europe conference in Prague. This special episode of BioCentury This Week has been brought to you by Jeito Capital.

View full story: https://www.biocentury.com/article/659450

#EuropeanBiotech #ClinicalDevelopment #BiopharmaInnovation #DrugDevelopment #LifeSciencesStrategy

00:01 - Sponsor Message: Jeito Capital 
03:14 - China’s Speed Challenge
04:08 - Europe’s Clinical Trial Opportunity
11:48 - Speed vs. Capital Efficiency
15:52 - Takeaways from Richard Pazdur
19:58 - FDA Uncertainty and Global Alternatives
26:50 - Biopharma M&A Outlook
33:34 - The Next Wave of Science

To submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected].

Reach us by sending a text